The Clorox (CLX) Price Target Lowered to $128.00 at Morgan Stanley

The Clorox (NYSE:CLX) had its target price reduced by equities research analysts at Morgan Stanley from $133.00 to $128.00 in a note issued to investors on Thursday. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price objective would suggest a potential downside of 0.40% from the company’s current price.

Other research analysts have also recently issued research reports about the stock. Deutsche Bank began coverage on shares of The Clorox in a research report on Wednesday, December 13th. They set a “hold” rating and a $142.00 price target on the stock. Wells Fargo reissued a “hold” rating and set a $130.00 price target on shares of The Clorox in a research report on Wednesday, December 13th. Jefferies Group reissued a “hold” rating and set a $130.00 price target on shares of The Clorox in a research report on Wednesday, December 13th. Bank of America raised shares of The Clorox from an “underperform” rating to a “neutral” rating and set a $155.00 price target on the stock in a research report on Thursday, January 4th. Finally, Zacks Investment Research raised shares of The Clorox from a “hold” rating to a “buy” rating and set a $163.00 price target on the stock in a research report on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the company. The Clorox presently has a consensus rating of “Hold” and an average price target of $132.18.

How to Become a New Pot Stock Millionaire

Shares of CLX opened at $128.51 on Thursday. The Clorox has a 52-week low of $123.64 and a 52-week high of $150.40. The company has a debt-to-equity ratio of 2.35, a quick ratio of 0.86 and a current ratio of 1.22. The firm has a market cap of $16,828.99, a price-to-earnings ratio of 24.02, a price-to-earnings-growth ratio of 2.69 and a beta of 0.35.

The Clorox (NYSE:CLX) last announced its earnings results on Friday, February 2nd. The company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.01. The Clorox had a net margin of 13.21% and a return on equity of 126.70%. The company had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter in the previous year, the company posted $1.14 EPS. The firm’s quarterly revenue was up .7% on a year-over-year basis. analysts forecast that The Clorox will post 5.67 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of CLX. Two Sigma Advisers LP lifted its position in The Clorox by 331.4% in the fourth quarter. Two Sigma Advisers LP now owns 815,434 shares of the company’s stock valued at $121,288,000 after buying an additional 626,426 shares during the last quarter. APG Asset Management N.V. lifted its position in The Clorox by 38.6% in the fourth quarter. APG Asset Management N.V. now owns 1,804,215 shares of the company’s stock valued at $223,483,000 after buying an additional 502,300 shares during the last quarter. Renaissance Technologies LLC lifted its position in The Clorox by 15.1% in the fourth quarter. Renaissance Technologies LLC now owns 2,360,600 shares of the company’s stock valued at $351,116,000 after buying an additional 310,000 shares during the last quarter. Schroder Investment Management Group lifted its position in The Clorox by 197.4% in the fourth quarter. Schroder Investment Management Group now owns 461,861 shares of the company’s stock valued at $68,697,000 after buying an additional 306,557 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. lifted its position in The Clorox by 196.0% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 430,313 shares of the company’s stock valued at $64,005,000 after buying an additional 284,937 shares during the last quarter. 75.71% of the stock is currently owned by institutional investors.

WARNING: This news story was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3336907/the-clorox-clx-price-target-lowered-to-128-00-at-morgan-stanley.html.

The Clorox Company Profile

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

Analyst Recommendations for The Clorox (NYSE:CLX)

Receive News & Ratings for The Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Clorox and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Head-To-Head Analysis: PHH  & Orix
Head-To-Head Analysis: PHH & Orix
Critical Survey: HTG Molecular Diagnostics  versus Coherent
Critical Survey: HTG Molecular Diagnostics versus Coherent
BitDice  Tops One Day Trading Volume of $2,352.00
BitDice Tops One Day Trading Volume of $2,352.00
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect NII  Share Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect NII Share Price
Electroneum Tops 1-Day Trading Volume of $1.27 Million
Electroneum Tops 1-Day Trading Volume of $1.27 Million
Reviewing William Demant  and Its Peers
Reviewing William Demant and Its Peers


© 2006-2018 Ticker Report. Google+.